We will be comparing the differences between Sienna Biopharmaceuticals Inc. (NASDAQ:SNNA) and Aeglea BioTherapeutics Inc. (NASDAQ:AGLE) as far as analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership are concerned. The two businesses are rivals in the Biotechnology industry.

Valuation & Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sienna Biopharmaceuticals Inc.	N/A	0.00	73.47M	-2.77	0.00
Aeglea BioTherapeutics Inc.	3.89M	53.74	44.35M	-1.88	0.00

Demonstrates Sienna Biopharmaceuticals Inc. and Aeglea BioTherapeutics Inc. earnings per share, top-line revenue and valuation.

Profitability

Table 2 demonstrates the return on equity, net margins and return on assets of Sienna Biopharmaceuticals Inc. and Aeglea BioTherapeutics Inc.

	Net Margins	Return on Equity	Return on Assets
Sienna Biopharmaceuticals Inc.	0.00%	-97.5%	-50.2%
Aeglea BioTherapeutics Inc.	-1,140.10%	-62.1%	-56%

Liquidity

The current Quick Ratio of Sienna Biopharmaceuticals Inc. is 4.9 while its Current Ratio is 4.9. Meanwhile, Aeglea BioTherapeutics Inc. has a Current Ratio of 9.4 while its Quick Ratio is 9.4. Aeglea BioTherapeutics Inc. is better positioned to pay off its short-term and long-term debts than Sienna Biopharmaceuticals Inc.

Analyst Recommendations

In next table is given Sienna Biopharmaceuticals Inc. and Aeglea BioTherapeutics Inc.’s ratings and recommendations.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Sienna Biopharmaceuticals Inc.	0	0	0	0.00
Aeglea BioTherapeutics Inc.	0	0	1	3.00

On the other hand, Aeglea BioTherapeutics Inc.’s potential upside is 93.10% and its average target price is $14.

Institutional and Insider Ownership

Roughly 32.3% of Sienna Biopharmaceuticals Inc. shares are held by institutional investors while 75.3% of Aeglea BioTherapeutics Inc. are owned by institutional investors. Insiders held roughly 4.3% of Sienna Biopharmaceuticals Inc.’s shares. Competitively, Aeglea BioTherapeutics Inc. has 1.1% of it’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Sienna Biopharmaceuticals Inc.	13.44%	7.09%	-71.81%	-83.09%	-82.01%	23.71%
Aeglea BioTherapeutics Inc.	-0.35%	-7%	-1.16%	-21.22%	23.91%	13.48%

For the past year Sienna Biopharmaceuticals Inc. has stronger performance than Aeglea BioTherapeutics Inc.

Summary

Aeglea BioTherapeutics Inc. beats Sienna Biopharmaceuticals Inc. on 7 of the 10 factors.

Sienna Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes topical products for medical dermatology and aesthetics markets in North America. The companyÂ’s lead product candidates include SNA-120, a TrkA inhibitor, which is in Phase 2b clinical development for the treatment of pruritus, itch, and neurogenic inflammation associated with psoriasis; and SNA-125, a dual JAK3/TrkA inhibitor that is in pre-clinical study for the treatment of atopic dermatitis, psoriasis, and pruritus. It also develops SNA-001, a photoparticle therapy, which is in pivotal clinical trials for the treatment of acne vulgaris and the reduction of unwanted light-pigmented hair. The company was formerly known as Sienna Labs, Inc. and changed its name to Sienna Biopharmaceuticals, Inc. in February 2016. Sienna Biopharmaceuticals, Inc. was founded in 2010 and is headquartered in Westlake Village, California.

Aeglea Biotherapeutics, Inc., a biotechnology company, develops enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer. Its human enzymes are designed to degrade specific amino acids in the blood. The companyÂ’s lead product candidate, AEB1102 is human Arginase I, engineered to reduce arginine levels to treat patients with Arginase I deficiency and patients with arginine-dependent solid tumors and hematological malignancies. Its pipeline of engineered human enzyme product candidates in preclinical development includes AEB3103, an enzyme that degrades the amino acids cysteine to target cancer to oxidative stress; AEB2109, an enzyme that degrades the amino acid methionine to target methionine dependent cancers; and AEB4104, an engineered human enzyme to treat another inborn errors of metabolism by degrading the amino acid homocysteine. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea Biotherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.